Agilent Technologies, Inc. Files Amended 8-K/A: Correction to Prior Filing and Executive Transition Agreement

Key Points from the Report

• Agilent Technologies, Inc. (NYSE: A) filed an amended 8-K/A on April 6, 2026, to correct an error in a previous 8-K submission filed on March 31, 2026.
• The amendment clarifies that the prior filing should have been made under Item 5.02 (“Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers”) instead of Item 5.01.
• The company disclosed details of a Transition Agreement with a departing executive, which could be material to investors.

Details of the Amendment and Executive Transition

Agilent Technologies, Inc. reported that its original Form 8-K, filed on March 31, 2026, was mistakenly identified as being made pursuant to Item 5.01. The sole purpose of this amendment is to correct the filing under Item 5.02, ensuring accurate regulatory and investor disclosures. The substance of the original 8-K and its attached exhibits remain unchanged.

Executive Transition Agreement – Material Terms

The report provides comprehensive details of a Transition Agreement for a departing executive, which is a potentially price-sensitive and material event for shareholders:

• Transition Period & Role:
  The executive will remain with the company during a defined Transition Period in the capacity of “Special Advisor.” During this period, the executive is classified as “remote” for work location purposes and is required to comply with all company policies, including confidentiality and standards of conduct.
• Compensation & Benefits:
  • Continued receipt of base salary paid on the standard US payroll schedule, subject to tax withholdings and deductions.
  • Healthcare benefits continue on the same basis as during the initial transition period.
  • Eligibility to participate in certain company benefits (including healthcare), but not eligible for any new or additional equity grants or participation in the annual Pay for Rewards (PFR) bonus for the financial year.
  • Equity vesting continues according to the terms of prior equity award agreements and the company’s 2018 Stock Plan, as amended.
• Severance and Final Payment:
  • The executive is entitled to a “Final Wage Payment,” but after this, the executive is not entitled to any further wages, bonuses, new equity awards, or other compensation or benefits from Agilent.
  • All company property (including devices, data, records, and confidential information) must be returned or destroyed within five business days after the transition period ends. This is a material condition for receiving transition benefits.
• Release of Claims:
  The executive releases Agilent, its affiliates, and related entities from any and all claims, including those related to equity, compensation, and employment matters. The agreement includes a full general release but does not prevent the executive from communicating with regulators such as the SEC.
• Confidentiality and Non-Disparagement:
  • The existence and terms of the agreement must be kept strictly confidential except as required by law or for discussions with immediate family, legal, or financial advisors.
  • There is a non-disparagement clause in effect once the second transition period begins, restricting the executive from making negative or disparaging statements about the company in any medium, including online and social media.
• Regulatory and Whistleblower Provisions:
  • The agreement specifically states nothing prohibits the executive from communicating with the SEC or participating in whistleblower activities, including receiving monetary awards from regulators.
  • The agreement includes a notice under the Defend Trade Secrets Act, affirming the executive’s right to disclose trade secrets to authorities for the purpose of reporting violations of law.
• No Liens or Pending Claims:
  The executive represents there are no pending lawsuits or claims against Agilent and agrees not to bring future claims.
• Medicare Reporting Obligations:
  • The executive must assist Agilent in any Medicare-related reporting required by law, and the company can delay settlement payments until such assistance is provided. The executive affirms whether or not they are Medicare-eligible.

Potential Shareholder Impact

This transition agreement is significant for investors as it involves the departure of a senior executive, continued vesting of equity awards (which could affect dilution and insider holdings), and clarifies the company’s obligations under regulatory and whistleblower laws.

• The lack of eligibility for new equity grants or annual bonuses for the departing executive may signal cost controls or changes in executive compensation philosophy.
• The non-disparagement and confidentiality clauses are standard but important for protecting the company’s reputation and sensitive information during executive transitions.
• The explicit SEC and whistleblower carve-outs ensure compliance with evolving regulatory expectations and may be viewed positively by governance-focused investors.

Investors should monitor for announcements regarding the identity of the executive, successor plans, and any further disclosures about leadership changes, as these could impact sentiment and share value.

Securities Registered

• Common Stock, \$0.01 par value
• Trading Symbol: A
• Exchange: New York Stock Exchange

Conclusion

The amended 8-K/A filing is primarily a technical correction but contains detailed disclosure about a high-level executive transition and compensation arrangements. Such disclosures can influence investor perception regarding leadership stability, compensation practices, and corporate governance at Agilent Technologies, Inc.

Disclaimer: This article is based on public filings made by Agilent Technologies, Inc. The information herein is intended for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.

View AGILENT TECHNOLOGIES, INC. Historical chart here